STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
clinical trial fda approval
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen to Acquire Reata Pharmaceuticals
acquisition
IMPACT
SENTIMENT
BIIB : Nasdaq
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
IMPACT
SENTIMENT
BIIB : Nasdaq
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
IMPACT
SENTIMENT
BIIB : Nasdaq IONS : Nasdaq
Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen)
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Announces Changes to Its Board of Directors
management
IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
IMPACT
SENTIMENT
BIIB : Nasdaq
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
IMPACT
SENTIMENT
BIIB : Nasdaq
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#421 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili